ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03220009
Recruitment Status : Withdrawn (The study was never approved by CTEP neither was it ever activated)
First Posted : July 18, 2017
Last Update Posted : October 3, 2018
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Estimated Primary Completion Date : July 1, 2021
  Estimated Study Completion Date : July 1, 2021